Dara Biosciences Quick Ratio (DARA) starting from the third quarter 2015 to third quarter 2014, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Dara Biosciences, Inc.  (DARA)

Dara Biosciences's Quick Ratio

DARA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2015, Quick Ratio fell to 2.02 below Dara Biosciences, Inc. average.

Within Major Pharmaceutical Preparations industry 187 other companies have achieved higher Quick Ratio than Dara Biosciences in third quarter 2015. While Quick Ratio total ranking in the third quarter 2015 has deteriorated compared to the prior quarter from to 1164.

Explain Quick Ratio?
How much Cash & cash equivalents DARA´s has?
What are DARA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DARA Quick Ratio (Sep 30 2015)
Q3		 (Jun 30 2015)
Q2		 (Mar 31 2015)
Q1		 (Dec 31 2014)
Q3		 (Sep 30 2014)
Q2
Y / Y Current Liabilities Change 23.1 % 12.71 % -7.02 % 10.07 % 48.42 %
Y / Y Cash & cash equivalent Change -66.73 % -55.9 % 44.29 % 251.09 % 441.74 %
Quick Ratio MRQ 2.02 3.81 6.28 6.52 7.48
DARA's Total Ranking # 1164 # # # #
Seq. Current Liabilities Change 25.34 % 17.24 % -14.94 % -1.52 % 14.76 %
Seq. Cash & cash equivalent Change -33.49 % -28.91 % -18.08 % -14.11 % -11.84 %



Quick Ratio third quarter 2015 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 188
Healthcare Sector # 329
Overall Market # 1164


Quick Ratio Statistics
High Average Low
10.54 4.66 0.79
(Jun 30 2012)   (Mar 31 2012)




Financial Statements
Dara Biosciences's Current Liabilities $ 2 Millions Visit DARA's Balance sheet
Dara Biosciences's Cash & cash equivalent $ 5 Millions Visit DARA's Balance sheet
Source of DARA's Sales Visit DARA's Sales by Geography


Cumulative Dara Biosciences's Quick Ratio

DARA's Quick Ratio for the trailling 12 Months

DARA Quick Ratio

 (Sep 30 2015)
12 Months		 (Jun 30 2015)
12 Months		 (Mar 31 2015)
12 Months		 (Dec 31 2014)
12 Months		 (Sep 30 2014)
12 Months
Y / Y Current Liabilities TTM Growth 10.05 % 13.88 % 15.75 % 25.28 % 14.83 %
Y / Y Cash & cash equivalent TTM Growth -16.43 % 49.32 % 191.15 % 167.05 % 87.4 %
Quick Ratio TTM 4.44 6.02 7.49 6.93 5.85
Total Ranking TTM # 3036 # # # #
Seq. Current Liabilities TTM Growth 6.07 % 3 % -1.68 % 2.46 % 9.77 %
Seq. Cash & cash equivalent TTM Growth -21.79 % -17.15 % 6.21 % 21.43 % 39.75 %

Quick ratio ranking by company, industry and sector >> Back to DARA Financial Strength Comparisons >> Go to Compare DARA Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q3 2015 to $2.30 millions, cumulative Quick Ratio decreased to 4.44 above the DARA average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 159 other companies have achieved higher Quick Ratio than Dara Biosciences. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2015 from to 3036.

Explain Quick Ratio?
How much Cash & cash equivalents DARA´s has?
What are DARA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 160
Healthcare Sector # 388
Within the Market # 3036


trailing twelve months Quick Ratio Statistics
High Average Low
5.67 4.27 3.25
(Mar 31 2013)   (Dec 31 2013)




Companies with similar Quick Ratio in the quarter ending Sep 30 2015, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2015 MRQ Cash & cash equivalentSep 30 2015 MRQ Current Liabilities
Alaunos Therapeutics Inc   5.53 $ 163.843  Millions$ 29.627  Millions
Ibio inc   5.36 $ 8.384  Millions$ 1.565  Millions
Evoke Pharma Inc   5.35 $ 10.739  Millions$ 2.006  Millions
Durect Corp  5.27 $ 32.194  Millions$ 6.104  Millions
Zogenix Inc   5.08 $ 177.813  Millions$ 35.026  Millions
Matinas Biopharma Holdings Inc   5.00 $ 4.363  Millions$ 0.873  Millions
Marinus Pharmaceuticals Inc   4.95 $ 33.001  Millions$ 6.663  Millions
Lexicon Pharmaceuticals Inc   4.95 $ 256.422  Millions$ 51.799  Millions
Viking Therapeutics Inc   4.90 $ 17.490  Millions$ 3.569  Millions
Oncomed Pharmaceuticals Inc  4.65 $ 175.205  Millions$ 37.690  Millions
Assembly Biosciences Inc   4.63 $ 65.968  Millions$ 14.252  Millions
Palatin Technologies Inc   4.48 $ 47.524  Millions$ 10.618  Millions
Cumberland Pharmaceuticals Inc   4.44 $ 52.755  Millions$ 11.875  Millions
Bio Green Med Solution Inc   4.32 $ 22.728  Millions$ 5.263  Millions
Evofem Biosciences Inc   4.26 $ 51.270  Millions$ 12.021  Millions
Vivus Inc  4.23 $ 251.087  Millions$ 59.401  Millions
Acura Pharmaceuticals inc  3.97 $ 15.253  Millions$ 3.839  Millions
Rigel Pharmaceuticals Inc  3.86 $ 134.350  Millions$ 34.838  Millions
Alkermes Plc   3.85 $ 771.761  Millions$ 200.402  Millions
Aveo Pharmaceuticals Inc   3.85 $ 40.102  Millions$ 10.417  Millions
Camp4 Therapeutics Corporation  3.82 $ 205.082  Millions$ 53.718  Millions
Arena Pharmaceuticals Inc   3.81 $ 181.280  Millions$ 47.578  Millions
Vbi Vaccines Inc  3.68 $ 11.009  Millions$ 2.989  Millions
Kyntra Bio Inc   3.61 $ 213.057  Millions$ 58.988  Millions
Emergent Biosolutions Inc   3.48 $ 308.718  Millions$ 88.725  Millions
Avenir Wellness Solutions Inc   3.38 $ 0.018  Millions$ 0.005  Millions
Arqule Inc  3.35 $ 43.759  Millions$ 13.064  Millions
Reshape Lifesciences Inc  3.33 $ 12.261  Millions$ 3.680  Millions
Cytokinetics Incorporated  3.25 $ 97.985  Millions$ 30.143  Millions
Myokardia Inc   3.24 $ 64.545  Millions$ 19.902  Millions

Date modified: 2026-09-02T17:50:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.